非布索坦

非布索坦（CAS 144060-53-7）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的理化数值

在册的记载用途

Febuxostat is indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of [allopurinol], who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. It is not recommended for the treatment of asymptomatic hyperuricemia or secondary hyperuricemia.Febuxostat received approval from the Food and Drug Administration (FDA) in 2009.

同义词与商品名

Febuxostat; 144060-53-7; Adenuric; Uloric; TMX-67; Tei 6720; Tei-6720; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid; TMX 67; Zurig; DTXSID8048650; Febuxostatum; NSC-758874; 101V0R1N2E; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid; 5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-

已收录的法规名录

GHS notification summary	5.9% (1 / 17)

GHS 危害分类

GHS notification summary	5.9% (1 / 17)
Reported hazard statements	H302 (88.2%), H362 (11.8%), H373 (11.8%), H413 (17.6%)

This chemical does not meet GHS hazard criteria for 5.9% (1 of 17) of reports.

H302 (88.2%): Harmful if swallowed [Warning Acute toxicity, oral]

公开数据库对它的描述

Febuxostat · CAS 144060-53-7 · C16H16N2O3S. UNII 101V0R1N2E. Melting Point: 238-239°; Solubility: <1 mg/mL.

物理形态与操作说明

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。